Drug Trial Radar · NCT00115570
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
Last checked: Nov 20, 2026Latest source record: May 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
572
Actual
Start
Apr 2005
Primary completion
Nov 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jun 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Conditions
- Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin glulisineDrug
Subcutaneous injection
insulin lisproDrug
Subcutaneous injection
insulin glargineDrug
Subcutaneous injection once daily
NPH insulinDrug
subcutaneous injection twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpointTime frame: week 26 or last observed treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.